Pharma data for AI research

Pharma data for a more complete answer.

Gosset connects drugs, trials, results, companies, patents and deals in one dataset. Bring that evidence into ChatGPT or Claude, or explore it in a Lens report.

Explore an example Connect your assistant

TL1A company bullseye from Gosset Lens, with drug candidates grouped by developer and development stage.

Trusted by teams in top-30 pharma, biotech, and life science investing

along with 3 top-30 pharma companies

Your assistant. Gosset’s data.

Keep ChatGPT or Claude.
Add Gosset.

Connect Gosset to the AI you already use. Give it a comprehensive, continuously updated pharma dataset to build on.

ChatGPT / Claude with web search

70%done

First draft that needs days of fact-checking

AI assistants don't know when the information they find online is stale or incomplete.

Coverage: What the search surfaces
Freshness: As current as the pages found
Sources: Mixed quality, often secondhand

Your assistant +

Gosset

99%done

Go deeper. Close the gaps.

Ground your analysis in connected pharma data, pulled directly for your question.

Coverage: Drugs, trials, results, companies & deals
Freshness: A continuously updated dataset
Sources: High-quality primary sources cited directly

More complete. More current.

Connected records reveal the assets, trials and relationships a web search can miss.

Backed by primary sources.

Peer-reviewed publications, abstracts, treatment guidelines, pipeline webpages, press releases, and more - all distilled into structured data

Less token overhead.

Less searching and extraction. More of your token budget goes into analysis.

Connect your assistant Explore an example

Questions Gosset helps answer.

Which drug candidates outperform the standard of care?: Safety and efficacy evidence is scattered across registries, publications and company disclosures.
What is the likelihood that this drug gets approved?: Broad benchmarks can miss the biology, patient population and design of your trial.
How much is this drug worth?: Valuations depend on assumptions about clinical success, timing, pricing and competition.
Which drug programs should we discontinue and which should we keep?: A competitor’s safety readout can change the risk before the next portfolio review.

What you can do with Gosset

Competitive Intelligence·Search & Evaluation·Trial Outcome Forecasting·Asset Due Diligence·Portfolio Optimization

Monitor

Competitive Intelligence

Safety, efficacy, trial design and biomarker data, connected to the source evidence.
Generate comprehensive landscapes for niche and nuanced indications with IP, pricing, and detailed development status.
Efficiently understand each drug's market positioning.
Get up to speed on the standard of care with reports backed by drug labels and current treatment guidelines.

See exactly what we cover →

Source

Search & Evaluation

Identify drug candidates that outperform the standard of care.
Build a shortlist of acquisition candidates from hundreds of pipeline assets.
Assess target validation, competitive crowding, and market potential.
Search across targets, indications, development stages and deal relationships.

Predict

Trial Outcome Forecasting

Calibrated estimates of clinical trial success.
Trial completion-date forecasts with a 47-day median improvement over sponsor estimates in our evaluation.
Custom models tuned to your company’s historical trials.

How we measure accuracy →

Validate

Asset Due Diligence

Bring your proprietary data together with Gosset’s knowledge graph.
Target validation informed by competing and discontinued programs.
Safety and efficacy benchmarking against competitors.
Market sizing informed by pricing data and epidemiology.
Patents, regulatory designations and exclusivity timelines.
Evidence-based risk analysis.

Prioritize

Portfolio Optimization

Recommendations based on your pipeline, resources and opportunities.
Account for time, cost and likelihood of success across each asset’s remaining trials.
Update risk assessments as competing programs develop.